¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"complement control protein"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • complement system
    º¸Ã¼°è, µµ¿òü°èÅë
  • complement-dependent cytotoxicity
    º¸Ã¼ÀÇÁ¸¼¼Æ÷µ¶¼º
  • complement-fixing antibody
    º¸Ã¼°áÇÕÇ×ü, µµ¿òü°áÇÕÇ×ü
  • complement-induced
    º¸Ã¼À¯µµ-
  • complement-mediated
    º¸Ã¼¸Å°³-
  • complement-mediated cytotoxicity
    º¸Ã¼¸Å°³¼¼Æ÷µ¶¼º
  • dominant complement
    ¿ì¼ºº¸Ã¼
  • accuracy control
    Á¤È®µµ°ü¸®
  • awaking drug control law
    °¢¼ºÁ¦Á¶Àý¹ý
  • air pollution control
    ´ë±â¿À¿°°ü¸®
  • biologics control laboratory
    »ý¹°Á¦Á¦°ü¸®½ÃÇè¼Ò
  • birth control
    »ê¾ÆÁ¦ÇÑ
  • bite control
    ±³ÇÕÁ¶Á¤
  • communicable disease control
    Àü¿°º´°ü¸®
  • conception control
    ¼öÅÂÁ¶Àý
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • structural protein
    ±¸Á¶´Ü¹é, ±¸Á¶´Ü¹éÁú
  • case-control study
    ȯÀÚ´ëÁ¶±º¿¬±¸
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • complement splitting
    µµ¿òüºÐ¿­, º¸Ã¼ºÐ¿­
  • complement system
    µµ¿òü°èÅë, º¸Ã¼°èÅë
  • complement typing
    º¸Ã¼Çüº°°Ë»ç
  • complement deficient state
    µµ¿òü°áÇÌ»óÅÂ, º¸Ã¼°áÇÌ»óÅÂ
  • complement fixation reaction
    º¸Ã¼°áÇÕ¹ÝÀÀ, µµ¿òü°áÇÕ¹ÝÀÀ
  • complement fixation test
    µµ¿òü°áÇÕ½ÃÇè, º¸Ã¼°áÇÕ½ÃÇè
  • complement fixation unit
    º¸Ã¼°áÇÕ´ÜÀ§
  • complement fixation inhibition test
    º¸Ã¼°áÇÕ¾ïÁ¦½ÃÇè
  • complement mediated lysis
    º¸Ã¼¸Å°³¿ëÇØ, µµ¿òü¸Å°³¿ëÇØ
  • complement-dependent cytotoxicity
    µµ¿òüÀÇÁ¸¼¼Æ÷µ¶¼º
  • complement-mediated cytotoxicity
    µµ¿òü°ü·Ã¼¼Æ÷µ¶¼º
  • dominant complement
    ¿ì¼ºµµ¿òü
  • adherence protein
    ºÎÂø´Ü¹é
  • antifreeze protein
    Ç×µ¿°á´Ü¹éÁú
  • protein binding
    ´Ü¹é°áÇÕ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • accuracy control
    Á¤È®¼º Á¶Àý
  • admission by legal control
    Á¶Ä¡ÀÔ¿ø.
  • air pollution control
    ´ë±â¿À¿°¹æÁö<±ÔÁ¦> (ÊÙËÑ̤<˻̡>).
  • gate control system
    °ü¹®Á¶Á¤ÀåÄ¡(μڦðàïÚíûöÇ).
  • gate control theory
    (°ü)¹®Á¶Àý¼³(μڦðàï½àã).
  • gonorrhea control
    ÀÓÁú°ü¸®.
  • hospital infection control
    ¿ø³»<º´¿ø>°¨¿°°ü¸®
  • idea of control
    Á¶ÀÛ°ü³ä
  • impulse control disorder
    Ãæµ¿ Á¶ÀýÀå¾Ö, ~º´
  • impulse-control disorder
    Ãæµ¿Á¶ÀýÀå¾Ö
  • infection control study
    °¨¿°°ü¸®¿¬±¸
  • infection control surveillance
    °¨¿°°ü¸®°¨½Ã
  • injury control
    »óÇØ°ü¸®(Ë×Ì´Ë´Ëö).
  • predictive value of control signal
    Á¦¾î<´ëÁ¶>½ÅÈ£ÀÇ ¿¹ÃøÄ¡
  • pulse control unit
    ¸Æ¹Ú Á¶Àý ´ÜÀ§
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • complement consumption test
    º¸Ã¼¼Òºñ½ÃÇè(¡­á¼Þ¨ãËúÐ).
  • complement consumption test
    º¸Ã¼¼Òºñ½ÃÇè(¡­á¼Þ¨ãËúÐ).
  • complement consumption test
    º¸Ã¼¼Òºñ½ÃÇè(¡­á¼Þ¨ãËúÐ).
  • complement deficiency
    º¸Ã¼°áÇÌ
  • complement deficient state
    º¸Ã¼°áÇÌ»óÅÂ
  • complement dependent cytotoxicity
    º¸Ã¼ÀÇÁ¸¼º ¼¼Æ÷µ¶¼º
  • complement fixation =CF
    º¸Ã¼°íÁ¤(¡­Í³ïÒ).
  • complement fixation =CF
    º¸Ã¼°áÇÕ(¡­Ì¿ùê).
  • complement fixation inhibition test
    º¸Ã¼°íÁ¤ÀúÇØ½ÃÇè(ÜÍô÷ͳïÒîÁúªãËúÐ).
  • complement fixation inhibition test
    º¸Ã¼°áÇÕÀúÇØ½ÃÇè(ÜÍô÷Ì¿ùêîÁúªãËúÐ).
  • complement fixation reaction
    º¸Ã¼°áÇÕ¹ÝÀÀ(¡­Úãëë).
  • complement fixation test
    º¸Ã¼°áÇÕ½ÃÇè
  • complement fixation test =CFT
    º¸Ã¼°íÁ¤½ÃÇè(¡­ãËúÐ).
  • complement fixation test =CFT
    º¸Ã¼°áÇÕ½ÃÇè(¡­ãËúÐ).
  • complement fixation test, indirect
    °£Á¢º¸Ã¼°áÇÕ½ÃÇè
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • control strengh
    Á¶Àý °­µµ(ðàï½Ë­Óø)
  • negative control
    À½Á¦¾î(ëäð¤åÙ)
  • negative gene control
    À½À¯ÀüÀÚÁ¦¾î(ëäë¶îîí­ð¤åÙ)
  • positive control
    "°¡Á¶Àý(ʦðàï½), ¾ç¼ºÁ¶Àý(åÕàõðàï½)"
  • positive gene control
    "°¡À¯ÀüÀÚÁ¶Àý(ʦë¶îîí­ðàï½), ¾ç¼ºÀ¯ÀüÀÚÁ¶Àý, (åÕàõë¶îîí­ðàï½)"
  • relaxed control
    ÀÌ¿Ï Á¶Àý(ì¬èÐðàï½)
  • respiratory control
    È£Èí Á¶Àý(ðàï½)
  • respiratory-control index
    È£Èí Á¶Àý Áö¼ö(ò¦â¦)
  • stereopopulation control
    ÀÔü±¸Á¶À̼ºÁúü(Ø¡ô÷ϰðãì¶àõòõô÷) Á¦¾î (ð¤åÙ)
  • stringent control
    ¾ö°Ý Á¦¾î (åñÌ«ð¤åÙ)
  • transcriptional control
    Àü»ç Á¦¾î(ï®ÞÐð¤åÙ)
  • translational control
    ¹ø¿ª Á¶Àý(Ûèæ»ðàï½)
  • zero time control
    ¿µ½Ã(çÍãÁ) ´ëÁ¶(ÓßðÎ)
  • accelerator protein
    ÃËÁø´Ü¹éÁú (õµòäÓ±ÛÜòõ)
  • acyl-carrier protein
    ¾Æ½Ç¿î¹Ý ´Ü¹éÁú (ê¡ÚæÓ±ÛÜòõ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • protein metabolism
    ´Ü¹é(Áú)´ë»ç
  • protein-losing enteropathy
    ´Ü¹é»ó½Ç¼ºÀ庴Áõ
  • protein-losing gastroenteropathy
    ´Ü¹é»ó½Ç¼ºÀ§ÀåÁõ
  • serum protein
    Ç÷û´Ü¹é
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MBP major basic protein; maltose-binding protein; management by policy; mannose-binding protein; mean bl...
RP radial pulse; radiopharmaceutical; rapid processing [of film]; Raynaud phenomenon; reactive protein;...
CPA Canadian Physiotherapy Association; Canadian Psychiatric Association; carboxypeptidase A; cardiopulm...
SC conditioned stimulus; sacrococcygeal; Sanitary Corps; scalenus [muscle]; scapula; Schwann cell; scia...
PCM patient care manager or management; patient classification system; primary cutaneous melanoma; proce...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ACP Alternative complement pathway
C Complement
C' 3 Complement
C3 Complement 3
CF Complement Fixation
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • control equipment
    Á¦¾î ÀåÄ¡
  • control gene
    Á¦¾î À¯ÀüÀÚ
  • control of bleeding
    ÁöÇ÷¹ý
  • control panel
    Á¶Á¾ÆÇ
  • control system
    Á¶Àý°è
  • control valve
    Á¶Àý ¹ëºê, Á¶ÀýÆÇ
  • laser hazard control measure
    ·¹ÀÌÀú À§ÇØÁ¶Àý¹ý
    ·¹ÀÌÀú°¡ Áö´Ñ ¾öû³­ ¿¡³ÊÁö´Â ÀÎü¿¡ ÇØ°¡ µÉ ¼ö ÀÖÀ¸¹Ç·Î µÇµµ·Ï ·¹ÀÌÀú¸¦ »ç¿ëÇÏ´Â »ç¶÷µéÀÌ ¼Õ»óÀ» ¹ÞÁö ¾Êµµ·Ï ÇÏ´Â ¹æ¹ý.
  • leprosy control
    ³ª °ü¸®
    °³³ä»ó, ÁÖ¹ÎÀ» ³ª±ÕÀÇ Àü¿°À¸·ÎºÎÅÍ º¸È£ÇÏ´Â ¿¹¹æ °ü¸®¿Í, ³ªÈ¯ÀÚ¸¦ ³ª±ÕÀ¸·ÎºÎÅÍ ¿À´Â À°Ã¼Àû, Á¤½ÅÀû °íÅëÀ» ´ú¾î ÁÖ´Â Áø·á °ü¸®ÀÇ µÎ °¡Áö·Î ºÐ·ùÇÒ ¼ö ÀÖ´Ù. ¨ç ¿¹¹æ °ü¸®´Â Àü¿°¿øÀ» Â÷´ÜÇÏ´Â °ÍÀ» ¸»Çϴµ¥, ³ª ȯÀÚ¸¦ °Ý¸®ÇÔÀ¸·Î½á ³ªº´ÀÇ Àü¿°¿øÀÌ Â÷´ÜµÈ´Ù°í »ý°¢Çß´ø ½Ã´ë¿¡´Â ³ª ȯÀÚ Àü¿øÀ» °Ý¸® ¼ö¿ëÇÏ¿´´Ù. ±×·¯³ª Àüü ³ª ȯÀÚ Áß ±ØÈ÷ ÀϺÎÀÇ ¹Ì°ü¸®ÇÏ¿¡ Àִ ȯÀÚ¸¸ÀÌ Àü¿°¿øÀÌ µÈ´Ù´Â »ç½ÇÀÌ ¹àÇôÁø ¿À´Ã³¯¿¡´Â, ³ª ȯÀÚ·Î È®ÀÎÀÌ µÇ¾î ¾àÁ¦ Åõ¿©°¡ ½ÃÀÛµÈ ÈÄ¿¡´Â Àü¿°¿øÀÌ µÉ ¼ö ¾ø´Ù´Â °á·Ð¿¡ À̸£·¶´Ù. ÀÌ¿¡ µû¶ó ¿À´Ã³¯¿¡´Â ÀÏ¹Ý ÇǺΠÁúȯÀÚ¿Í °°ÀÌ ÀÚÀ¯·ÎÀÌ »ý¾÷¿¡ Á¾»çÇϸç Áø·á¸¦ ¹Þ°í ÀÖ´Ù. ¨è Áø·á °ü¸®´Â Àǻ簡 Á¤È®ÇÑ Áø´Ü°ú º´Çü ºÐ·ù¸¦ ¹ÙÅÁÀ¸·Î ÀûÇÕÇÑ Ã³¹æÀ» ³»¸®°í ȯÀÚ°¡ ¼º½ÇÇÏ°Ô ¾àÀ» º¹¿ëÇÏ´Â °ÍÀÌ´Ù. ¹®Á¦´Â ³ªº´ÀÌ ¸¸¼ºÀûÀ¸·Î °æ°úÇÏ´Â Àå±â ÁúȯÀε¥´Ù Ä¡·áÀÇ ¼º°ú°¡ Áï½Ã ³ªÅ¸³ªÁö ¾ÊÀ¸¹Ç·Î 󹿰ú º¹¾àÀÌ ³ªÅÂÇØÁ® Ä¡·á°¡ ºÒ±ÔÄ¢ÇØÁö°í ¾àÁ¦ ³»¼ºÀ» ¹ßÀü½ÃŰ´Â µ¥ µû¸¥ °ü¸®»óÀÇ ¾î·Á¿òÀÌ ÀÖ´Ù. ³ªº´¿¡ ´ëÇÑ Æí°ßÀ» ¾ø¾Ö°í ±¹¹ÎÀû ÀÌÇØ¿Í Âü¿©¿¡ ÀÇÇØ Á¶±â ¹ß°ß ¹× Ä¡·á¿¡ ÀÓÇÑ´Ù¸é ³ªº´ °ü¸®¸¦ À§ÇÑ Æ¯¼ö ½Ã¼³À̳ª ±â°üÀÌ ÇÊ¿ä¾ø°Ô µÉ °ÍÀÌ´Ù.
  • nociceptive control
    Ä§ÇØ ¼ö¿ë¼º Á¶Àý, À¯ÇØ ¼ö¿ë¼º Á¶Àý
  • pest control
    À¯ÇØ »ý¹° Á¦¾î
  • plaque control
    ġŠÁ¶Àý
  • proper direction and control
    ÀûÀýÇÑ Áöµµ¿Í ÅëÁ¦
  • pulse control unit
    ¸Æ¹Ú Á¶Àý ´ÜÀ§
  • quality control program
    Á¤µµ °ü¸® °èȹ
  • reasonable emotional control
    ÇÕ¸®Àû Á¤¼­ Á¶Àý
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
complement 3b <chemical> The larger fragment formed when c3 convertase splits c3 into c3a and c3b. In both the classical and alternate pathway, c3b participates in immune adherence and enhances phagocytosis. It also forms a cellular intermediate which continues the complement process. In the alternate pathways, c3b initiates a positive feedback activation of c3pase.
Chemical name: Complement C3b
(12 Dec 1998)
complement 3b inactivators Compounds which inhibit, antagonise, or inactivate complement 3b. A well-known inhibitor is a beta-globulin which cleaves c3b into inactive fragments c3c and c3d. C3bina plays a key role in the regulation of the complement system by blocking the cytolytic sequence and preventing recruitment of the properdin amplification loop.
(12 Dec 1998)
complement 3c <chemical> An inactivated form of complement 3b (c3b). Complement 3b is inactivated with the help of two regulatory factors, complement factor h and complement factor I. Complement factor h (c3b inactivator accelerator) makes c3b susceptible to the serine protease, complement factor I (formerly called kaf, c3binf, or enzyme 3b inactivator), to form ic3b. Then complement factor I and a trypsin-like proteolytic enzyme further cleave ic3b into c3c and c3dg.
Chemical name: Complement C3c
(12 Dec 1998)
complement 3 convertase <enzyme> The enzyme which in both the classical and alternate complement pathways cleaves complement 3 into anaphylatoxin (c3a) and c3b.
Registry number: EC 3.4.21.43
(12 Dec 1998)
complement 3d <chemical> An inactivated fragment of complement 3b (c3b). Factor h makes c3b susceptible to factor I (formerly called kaf, c3binf, or enzyme 3b inactivator) to form ic3b. Then factor I and a trypsin-like proteolytic enzyme further cleave ic3b into c3c and c3dg. Serum proteases degrade c3dg into complement 3d (c3d) and c3g.
Chemical name: Complement C3d
(12 Dec 1998)
complement 3 nephritic factor A magnesium-dependent IgG autoantibody found in serum of patients with chronic mesangioproliferative hypocomplementemic glomerulonephritis. It causes inactivation of c3 in the alternate pathway by cleaving c3 into two inactive fragments, c3c and c3d, instead of the normal c3b.
(12 Dec 1998)
complement 4 The second component to react in the complement sequence. It is a beta-globulin with a sedimentation coefficient of 18.7, a molecular weight of 240,000 and a serum concentration of 430 micrograms/ml. It is activated by complement 1 and serves as a receptor for c2.
(12 Dec 1998)
complement 4a <chemical> Smaller fragment formed when c1s splits c4 into c4a and c4b. As an anaphylatoxin, c4a causes symptoms of immediate hypersensitivity but it has weaker activity than c3a or c5a.
Chemical name: Complement C4a
(12 Dec 1998)
complement 4b <chemical> Larger fragment formed when c1s splits c4 into c4a and c4b. C4b combines with c2b to form the activated c4b2b complex which is often called the classical pathway c3 convertase.
Chemical name: Complement C4b
(12 Dec 1998)
complement 5 The fifth component in the complement reaction sequence, probably exists in a complex with c6 and c7. It is a beta-globulin with a sedimentation coefficient of 10, serum concentration of 75 micrograms/ml and molecular weight of 180,000. It is activated by c423 and releases fragments with anaphylatoxic, chemotactic, and histamine-releasing actions and affecting smooth muscle.
(12 Dec 1998)
complement 5a <chemical> Smaller fragment formed when c5 convertase splits c5 into c5a and c5b. C5a is a 74-amino acid peptide that includes a carboxy-terminal arginine crucial for its spasmogenic activity and a carbohydrate moiety. C5a is the most potent anaphylatoxin mediating immediate hypersensitivity.
Chemical name: Complement C5a
(12 Dec 1998)
complement 5a, des-arginine Complement 5a with the carboxy-terminal arginine removed. The arginine is rapidly cleaved from the c5a fragment during complement activation by carboxypeptidase b present in normal human serum. C5a des-arg shows complete loss of spasmogenic activity though it retains some chemotactic ability.
(12 Dec 1998)
complement 6 The sixth component in the complement reaction sequence. It is a beta-globulin with a sedimentation coefficient of 8.7 and a molecular weight of 120,000 at 60 micrograms/ml in serum. It may exist in a complex with c5 and c7 and is activated by the binding of c5.
(12 Dec 1998)
complement 7 The seventh component in the complement reaction sequence. It is a beta-globulin probably in a complex with c5 and c6 and is activated by c5. The attachment of c7 renders the cell susceptible to lysis.
(12 Dec 1998)
complement 8 The next to the last essential component for cell lysis in the complement reaction sequence. It is a gamma-globulin with a molecular weight of 150,000 and a sedimentation coefficient of 8. It is present in trace amounts in serum and can be inhibited, like complement 1, by cation chelators.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • automatic train control
    ¿­Â÷ÀÚµ¿Á¦¾îÀåÄ¡
  • birth control
    »ê¾Æ Á¦ÇÑ
  • central control station
    Áß¾ÓÁ¦¾î±¹
  • civilian control
    ¹®°ü ¿ìÀ§(Áö¹è)
  • conception control
    ¼öÅ Á¶Àý;ÇÇÀÓ
  • control
    Áö¹è;´Ü¼Ó;°ü¸®;°¨µ¶(±Ç);¾ïÁ¦;Á¦¾î;±ÔÁ¦;Á¦±¸(·Â);ÄÁÆ®·Ñ;ÅëÁ¦(°üÁ¦)¼ö´Ü;(±â°èÀÇ)Á¶Á¾(Á¦¾î)ÀåÄ¡;(½ÇÇèÀÇ)´ëÁ¶Ç¥ÁØ;´ëÁ¶±¸;¿µ¸Å¸¦ Áö¹èÇÏ´Â Áö¹è·É;(ÀÚµ¿Â÷°æÁֵ¼­ °£´ÜÇÑ ¼ö¸®¸¦ À§ÇÑ)°æÁÖ Áߴܱ¸¿ª;Á¦¾î;Áö¹èÇÏ´Ù;ÅëÁ¦(°üÁ¦)ÇÏ´Ù;°¨µ¶ÇÏ´Ù;°ü¸®ÇÏ´Ù;¾ïÁ¦(Á¦¾î)ÇÏ´Ù;(
  • control board
    Á¦¾î¹Ý
  • control booth
    (¶óµð¿À.TV)Á¦¾î½Ç;Á¶Á¤½Ç
  • control chart
    °ü¸®µµ(ƯÈ÷ Á¦Ç° ǰÁúÀÇ)
  • control clock
    ±âÁØ ½Ã°è(master clock)
  • control column
    Á¶Á¾·û(Â÷ÀÇ ÇÚµé½Ä Á¶Á¤°£)
  • control experiment
    ´ëÁ¶ ½ÇÇè
  • control grid
    (ÀüÀÚ°üÀÇ)Á¦¾î ±×¸®µå(°ÝÀÚ)
  • control group
    Á¦¾îÁý´Ü;Á¶Á¾ÀåÄ¡;´ëÁ¶±º(µ¿ÀϽÇÇè¿¡¼­ ½ÇÇè¿ä°ÇÀ» °¡ÇÏÁö ¾ÊÀº ±×·ì)
  • control lever
    =CONTROL STICK
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á